-
公开(公告)号：US20200093750A1
公开(公告)日：2020-03-26
申请号：US16695498
申请日：2019-11-26
IPC分类号： A61K9/28 , A61K31/155
摘要： Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.
-
公开(公告)号：US09486463B2
公开(公告)日：2016-11-08
申请号：US13276177
申请日：2011-10-18
IPC分类号： A61K9/28 , A61P3/04 , A61P3/10 , A61K31/7016 , A61K31/155 , A61K31/194 , A61K31/198 , A61K31/216 , A61K31/353 , A61K31/4709 , A61K31/575 , A61K31/7032 , A61K31/704 , A61K45/06
CPC分类号： A61K31/7016 , A61K31/155 , A61K31/194 , A61K31/198 , A61K31/216 , A61K31/353 , A61K31/4709 , A61K31/575 , A61K31/7032 , A61K31/704 , A61K45/06 , A61K2300/00
摘要： Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.
摘要翻译： 本文提供调节受试者中激素浓度的方法，包括施用包含化学感应受体配体的组合物，其中所述组合物适于将配体递送至所述受试者的肠道的一个或多个区域。 还提供了用于调节GLP-1（总），GLP-1（活性），GLP-2，胃泌酸调节蛋白，PYY（总），PYY 3-36，CCK，GIP中的一种或多种的循环浓度的方法， 胰岛素，C-肽，甘氨酸，尿鸟嘌呤基胰岛淀粉样多肽和生长素释放肽（总），生长素释放肽（活性）和胰高血糖素。
-
公开(公告)号：US09480663B2
公开(公告)日：2016-11-01
申请号：US14370449
申请日：2012-07-11
IPC分类号： A61P3/10 , A61K9/22 , C07C279/26 , A61K31/155 , A61K45/06 , A61K31/55 , A61K31/137 , A61K31/357 , A61K31/485 , A61K9/24 , A61K9/28 , A61K31/7048 , A61K9/20
CPC分类号： A61K31/155 , A61K9/2018 , A61K9/2054 , A61K9/209 , A61K9/2846 , A61K31/137 , A61K31/357 , A61K31/485 , A61K31/55 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要： Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
摘要翻译： 本文提供了通过施用包含双胍或相关杂环化合物（例如二甲双胍）的组合来治疗某些病症（包括糖尿病，肥胖症和其它代谢疾病，病症或病症）的方法。 本文还提供双胍类或相关杂环化合物组合物及其制备用于本发明方法的方法。 本文还提供包含二甲双胍及其盐及其使用方法的组合物。
-
公开(公告)号：US20130137631A1
公开(公告)日：2013-05-30
申请号：US13591677
申请日：2012-08-22
申请人： Odile Esther LEVY , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther LEVY , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： C07K14/575 , C07K7/06
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
-
公开(公告)号：US08404637B2
公开(公告)日：2013-03-26
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
-
6.发明授权Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease 有权毒蜥外泌肽治疗非酒精性脂肪性肝炎和非酒精性脂肪性肝病公开(公告)号：US08389472B2
公开(公告)日：2013-03-05
申请号：US12063712
申请日：2006-08-21
申请人： Alain D. Baron , Dennis Kim , David G. Maggs , Matthew Wintle
发明人： Alain D. Baron , Dennis Kim , David G. Maggs , Matthew Wintle
CPC分类号： A61K38/22 , A61K38/2278 , A61K38/26
摘要： The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.
摘要翻译： 本发明一般涉及肠降血候素化合物（IC）和胰岛淀粉样多模组合物治疗，预防或改善各种代谢疾病或疾病的新用途。
-
7.发明申请公开(公告)号：US20110136737A1
公开(公告)日：2011-06-09
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： A61K38/22 , C07K14/645 , C07K14/605 , A61K38/26 , A61P3/10 , A61P9/00
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
8.发明申请公开(公告)号：US20100323955A1
公开(公告)日：2010-12-23
申请号：US12742918
申请日：2007-11-14
CPC分类号： A61K38/2264 , A61K31/137 , A61K31/155 , A61K31/35 , A61K38/22 , A61K38/2278 , A61K2300/00
摘要： Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
摘要翻译： 公开了治疗肥胖或肥胖相关疾病的方法。 这些方法包括使用针对前脑的抗肥胖剂与针对后脑的抗肥胖剂的组合。
-
9.发明申请公开(公告)号：US20090156474A1
公开(公告)日：2009-06-18
申请号：US11665675
申请日：2005-11-01
IPC分类号： A61K38/22 , A61K31/718
CPC分类号： A61K38/2264 , A61K31/137 , A61K31/454 , A61K38/22 , A61K38/2207 , A61K38/2278 , A61K38/25 , A61K38/26 , A61K45/06 , A61K2300/00
摘要： Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
摘要翻译： 公开了治疗肥胖或肥胖相关疾病的方法。 这些方法包括使用针对前脑的抗肥胖剂与针对后脑的抗肥胖剂的组合。
-
公开(公告)号：US09050292B2
公开(公告)日：2015-06-09
申请号：US13978514
申请日：2012-01-06
申请人： Alain D. Baron , Martin R. Brown , Christopher R. G. Jones , Nigel R. A. Beeley , Mark S. Fineman
发明人： Alain D. Baron , Martin R. Brown , Christopher R. G. Jones , Nigel R. A. Beeley , Mark S. Fineman
IPC分类号： A61K31/155 , A61K9/20 , A61K9/24 , A61K9/28 , A61K9/48 , A61K9/00 , A61K31/19 , A61K31/198 , A61K31/7016 , A61K31/704 , A61K45/06
CPC分类号： A61K31/155 , A61K9/0053 , A61K9/2054 , A61K9/209 , A61K9/2846 , A61K9/4808 , A61K31/19 , A61K31/198 , A61K31/7016 , A61K31/704 , A61K45/06
摘要： Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
摘要翻译： 本文提供了通过施用包含化学感应受体配体如苦味受体配体的组合物来治疗与化学感觉受体相关的病症（包括糖尿病，肥胖症和其它代谢疾病，病症或病症）的方法。 本文还提供了化学感应受体配体组合物，包括苦味受体配体组合物及其制备用于本发明方法的方法。 本文还提供包含二甲双胍及其盐及其使用方法的组合物。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.067 秒)
